Abstract
Ingle and colleagues present timely findings identifying genetic variants associated with response to selective estrogen receptor modulator therapy that when substantiated in follow-up may represent an important step toward understanding estrogen-dependent induction of BRCA1 expression and advancing individualized preventive medicine in women at high risk for developing breast cancer.
Original language | English (US) |
---|---|
Pages (from-to) | 728-729 |
Number of pages | 2 |
Journal | Cancer discovery |
Volume | 3 |
Issue number | 7 |
DOIs | |
State | Published - Jul 2013 |
Externally published | Yes |
ASJC Scopus subject areas
- Oncology